metformin has been researched along with Lung Adenocarcinoma in 11 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, the combined effects of metformin and gefitinib were examined in vivo in a mouse xenograft model, inoculated with a human lung adenocarcinoma cell line that possesses an activating epidermal growth factor receptor mutation." | 7.79 | Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. ( Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O, 2013) |
| " This study aimed to explore the real-world use of anti-diabetic agent metformin in combination with pemetrexed-based platinum doublets in a first-line setting." | 5.62 | Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. ( Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC, 2021) |
| " In the present study, the combined effects of metformin and gefitinib were examined in vivo in a mouse xenograft model, inoculated with a human lung adenocarcinoma cell line that possesses an activating epidermal growth factor receptor mutation." | 3.79 | Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. ( Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O, 2013) |
| "Metformin use was associated with improved survival, especially LCSS in patients with regional stage SCC." | 1.62 | Metformin use and lung cancer survival: a population-based study in Norway. ( Botteri, E; Brancher, S; Damhuis, RAM; Johannesen, TB; Strand, TE; Støer, NC; Weiderpass, E, 2021) |
| " This study aimed to explore the real-world use of anti-diabetic agent metformin in combination with pemetrexed-based platinum doublets in a first-line setting." | 1.62 | Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. ( Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 6 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Arrieta, O | 2 |
| Zatarain-Barrón, ZL | 2 |
| Turcott, JG | 1 |
| Barrón, F | 1 |
| Yendamuri, S | 1 |
| Cardona, AF | 1 |
| Rosell, R | 1 |
| Qiu, C | 1 |
| Li, C | 1 |
| Zheng, Q | 1 |
| Fang, S | 1 |
| Xu, J | 1 |
| Wang, H | 2 |
| Guo, H | 1 |
| Li, L | 1 |
| Jiang, L | 1 |
| Wang, Y | 1 |
| Zhao, Y | 1 |
| Zhang, XJ | 1 |
| Wu, G | 1 |
| Zhou, X | 1 |
| Sun, J | 1 |
| Bai, J | 1 |
| Ren, B | 1 |
| Tian, K | 1 |
| Xu, Z | 1 |
| Xiao, HL | 1 |
| Zhou, Q | 1 |
| Han, R | 1 |
| Chen, H | 1 |
| Yang, Z | 1 |
| Gao, C | 2 |
| Cai, S | 2 |
| He, Y | 2 |
| Ramirez-Tirado, LA | 1 |
| Brancher, S | 1 |
| Støer, NC | 1 |
| Weiderpass, E | 1 |
| Damhuis, RAM | 1 |
| Johannesen, TB | 1 |
| Botteri, E | 1 |
| Strand, TE | 1 |
| Wang, JL | 1 |
| Tsai, YT | 1 |
| Lin, CH | 1 |
| Cidem, A | 1 |
| Staniczek, T | 1 |
| Chang, GR | 1 |
| Yen, CC | 1 |
| Chen, W | 1 |
| Chong, KY | 1 |
| Chen, CM | 1 |
| Vernieri, C | 1 |
| Signorelli, D | 1 |
| Galli, G | 1 |
| Ganzinelli, M | 1 |
| Moro, M | 1 |
| Fabbri, A | 1 |
| Tamborini, E | 1 |
| Marabese, M | 1 |
| Caiola, E | 1 |
| Broggini, M | 1 |
| Hollander, L | 1 |
| Gallucci, R | 1 |
| Vandoni, G | 1 |
| Gavazzi, C | 1 |
| Triulzi, T | 1 |
| Colombo, MP | 1 |
| Rizzo, AM | 1 |
| Corsetto, PA | 1 |
| Pruneri, G | 1 |
| de Braud, F | 1 |
| Sozzi, G | 1 |
| Torri, V | 1 |
| Garassino, MC | 1 |
| Lee, BB | 1 |
| Kim, Y | 1 |
| Kim, D | 1 |
| Cho, EY | 1 |
| Han, J | 1 |
| Kim, HK | 1 |
| Shim, YM | 1 |
| Kim, DH | 1 |
| Kitazono, S | 1 |
| Takiguchi, Y | 2 |
| Ashinuma, H | 1 |
| Saito-Kitazono, M | 1 |
| Kitamura, A | 1 |
| Chiba, T | 1 |
| Sakaida, E | 1 |
| Sekine, I | 2 |
| Tada, Y | 2 |
| Kurosu, K | 1 |
| Sakao, S | 1 |
| Tanabe, N | 1 |
| Iwama, A | 2 |
| Yokosuka, O | 1 |
| Tatsumi, K | 2 |
| Kurimoto, R | 1 |
| Iwasawa, S | 1 |
| Ebata, T | 1 |
| Ishiwata, T | 1 |
| Koide, S | 1 |
3 trials available for metformin and Lung Adenocarcinoma
| Article | Year |
|---|---|
Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma of Lung; Body Mass Index; ErbB Receptors; Humans; Lung Neoplasms; Metformin; Mutation | 2022 |
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non- | 2019 |
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; AMP-Activated Protein Kinase Kinases; Antineoplasti | 2019 |
8 other studies available for metformin and Lung Adenocarcinoma
| Article | Year |
|---|---|
Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung; Lung Neo | 2022 |
Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Metf | 2020 |
Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Metf | 2020 |
Metformin use and lung cancer survival: a population-based study in Norway.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lu | 2021 |
Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Complications | 2021 |
Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
Topics: Acetylation; Adenocarcinoma of Lung; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Ap | 2019 |
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.
Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combine | 2013 |
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell | 2016 |